Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Autism Spectrum Disorder (ASD) is a neurodegenerative disorder which is associated and often overlaps with other conditions such as epilepsy, frequent infections, sleep disorders, anxiety, depression, and gastrointestinal problems. ASD is only diagnosed by developmental and comprehensive tests. It can be detected at eighteen months to two years of age. Drugs such as Aripiprazole, Risperidone, and Melatonin are U.S. Food and Drug Administration (FDA) approved drugs that aid in the treatment of ASD. Bumetanide and Balovaptan are the drugs that are under clinical trial and investigation to evaluate their safety and efficacy for the treatment of ASD.
The global autism spectrum disorder therapeutics market was valued at US$ 2,285.5 million in 2018, and is expected to witness a CAGR of 10.9% over the forecast period (2019 – 2027).
Increasing Number of Pipeline Drugs and Early Diagnosis of ASD is expected to Drive Growth of the Autism Spectrum Disorder Therapeutics Market
Increasing number of pipeline drugs and launches of novel products by key players are expected to be major factors driving the global autism spectrum disorder therapeutics market growth during the forecast period. For instance, in February 2014, the company was awarded six new patents for its enzyme delivery system in Europe, Australia, and Central America, which can be utilized for multiple enzyme products including CM-AT— Curemark’s proprietary ASD drug.
Furthermore, in September 2017, Curemark conducted second Phase III clinical trial: Blüm Study — to evaluate the safety and efficacy of CM-AT in children aged 3-8 with ASD.
Moreover, early diagnosis of ASD can aid in the development of children. For instance, according to a research published in the JAMA Pediatrics journal in April 2019, accurate diagnosis of ASD at 18 months or earlier is feasible and there may be opportunities to test the usefulness of ASD treatment at an early age. Therefore, increasing research on ASD is expected to create a favorable environment for autism spectrum disorder therapeutics market growth over the forecast period.
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Get Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-pdf/2643
Autism Spectrum Disorder Therapeutics Market – Restraints
Shortage of specialised doctors to diagnose ASD accurately is one of the major factors, which is expected to hamper the ASD therapeutics market. For instance, according to Simons Foundation Autism Research Initiative (SFARI), in 2018, there were only 8,300 child psychiatrists, 1,500 child neurologists, and 1,000 developmental-behavioral pediatricians for over 1 million autistic children in the U.S. The shortage of specialist doctors to diagnose ASD is expected to hamper growth of the ASD therapeutic market.
Autism Spectrum Disorder Therapeutics Market – Regional Insights
On the basis of region, the global autism spectrum disorder therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global autism spectrum disorder therapeutics market during the forecast period owing to increasing prevalence of ASD in the pediatric population of the U.S. For instance, according to the Centers for Disease Control and Prevention’s (CDC) report released in April 2018, 1 in every 59 children was identified with ASD in the age group of 3 to 17 years in 2014.
Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2643
Asia Pacific is expected to witness a rapid growth in the autism spectrum disorder therapeutics market revenue. This is owing to increase in sales of Aripiprazole for the treatment of ASD. For instance, in 2017, Otsuka Pharmaceutical’s ABILIFY MAINTENA (Aripiprazole) generated a revenue of US$ 62.9 million with a growth of 24.1% compared to 2016. Moreover, ABILIFY accounted for a revenue of US$ 59.7 million in 2017.
Autism Spectrum Disorder Therapeutics Market – Competitive Landscape
Key players operating in the global autism spectrum disorder therapeutics market include F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.
Detailed Segmentation:
- Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:
- Aripiprazole
- Risperidone
- Melatonin
- CM-AT
- Bumetanide
- Balovaptan
- Global Autism Spectrum Disorder Therapeutics Market, By Age Group:
- Child
- Adult
- Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Browse Press Release: https://bit.ly/2Az92R6
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
